一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 1.1500 | 1.1500 | 0 | 1.1800 | | 每股净资产（元） | 15.39 | 14.58 | 5.56 | 10.15 | | 每股公积金(元) | 7.68 | 7.69 | -0.13 | 2.99 | | 每股未分配利润(元) | 6.21 | 5.40 | 15 | 5.68 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 9.74 | 9.81 | -0.71 | 9.74 | | 净利润(亿元) | 1.2 | 1.1 | 9.09 | 1.01 | | 净资产收益率(%) | 7.56 | 9.04 | -16.37 | 11.62 | | 名称 | 持有数量(万股) | 占总股本 | 增减情况 | | --- | --- | --- | --- | | | | 比例(%) | (万股) | | 谢晓林 ...

Financial Performance - The company reported a double-digit growth in sales revenue, with a significant increase in its main products, indicating a robust performance in the past year[7]. - The company's operating revenue for 2024 is approximately ¥973.86 million, a decrease of 0.71% compared to ¥980.83 million in 2023[24]. - Net profit attributable to shareholders for 2024 is approximately ¥120.27 million, an increase of 8.91% from ¥110.43 million in 2023[24]. - The net cash flow from operating activities for 2024 is approximately ¥156.59 million, representing a significant increase of 50.50% compared to ¥104.05 million in 2023[24]. - Total assets at the end of 2024 amount to approximately ¥2.28 billion, reflecting a growth of 7.29% from ¥2.13 billion at the end of 2023[24]. - The net assets attributable to shareholders at the end of 2024 are approximately ¥1.64 billion, an increase of 5.56% from ¥1.55 billion at the end of 2023[24]. - Basic earnings per share for 2024 remain stable at ¥1.15, unchanged from 2023[24]. - The diluted earnings per share for 2024 is ¥1.15, an increase of 1.77% from ¥1.13 in 2023[24]. - The weighted average return on equity for 2024 is 7.56%, down from 9.04% in 2023[24]. - The company reported a quarterly revenue of approximately ¥261.57 million in Q3 2024, showing a steady performance[28]. Product Development and Innovation - The company successfully registered 211 varieties of formula granules, marking a breakthrough from zero to market entry[7]. - The company is focusing on innovation, with accelerated clinical exploration of its self-developed traditional Chinese medicine PLZY-001 and successful completion of pilot tests for several chemical generic drugs[9]. - The strategic goal is to establish a leading brand in the treatment of rheumatism and bone injuries, with a clear product pipeline that includes both oral and external applications[9]. - The company aims to implement a "21355" product cultivation target to drive innovation and development in key therapeutic areas[12]. - The company is focused on expanding its market presence and enhancing its product lineup, including proprietary health products and functional health foods[44]. - The company has established a diversified R&D system focusing on high-end new drug development, with multiple research centers and partnerships with top universities and research institutions[78]. - The company is accelerating the development of new products such as PLJT-001, PLJT-002, PLJT-003, and PLJT-004, aiming to create a comprehensive product pipeline[79]. - The company aims to develop over 400 products in the traditional Chinese medicine formula granules category, with 211 national standard varieties already developed[115]. Market Strategy and Expansion - The company aims to enhance its governance level through a comprehensive "one center, four platforms" R&D system and improve production quality through digital management[12]. - The company plans to implement a "21355" product cultivation target to drive innovation and development in key therapeutic areas[12]. - The company is focusing on a three-pronged development model: "policy decoding, innovation transformation, and ecological empowerment" to enhance its market position[35]. - The company has established a marketing network in 30 provinces, with over 630 pharmaceutical companies and coverage in more than 4,800 hospitals and 7,000 pharmacies[81]. - The company is actively involved in the development of new technologies and products, aiming to strengthen its competitive position in the pharmaceutical industry[44]. - The company has established a market expansion strategy that includes developing untapped county-level markets for its products[148]. Social Responsibility and Community Engagement - The company is committed to social responsibility, engaging in various initiatives from medical supply support to rural revitalization[11]. - The company is actively participating in social responsibility initiatives, including rural revitalization and public welfare activities[144]. - The company expressed gratitude to investors and partners, emphasizing the importance of community support in its growth journey[11]. Governance and Compliance - The company has established a complete and independent governance structure, ensuring compliance with relevant laws and regulations[154]. - The board of directors consists of nine members, including three independent directors, meeting legal requirements[157]. - The company has implemented a robust internal control system, with the audit department conducting audits to ensure compliance with regulations[163]. - The company maintains a clear separation from its controlling shareholder in terms of business, personnel, assets, and finance, ensuring independent operations[166]. - The company has a complete set of assets necessary for production and operations, including land use rights and equipment[167]. Financial Management and Investments - The company has received multiple awards for its products, including recognition as a top brand in the category of common household medications for rheumatic bone diseases[76]. - The company has received administrative regulatory measures from the China Securities Regulatory Commission in January 2024[194]. - The total amount of funds raised in 2023 through a private placement was ¥294.84 million, with a net amount of ¥294.84 million after deducting issuance costs[127]. - The total amount of funds raised in 2022 through public convertible bonds was ¥271.98 million, with a net amount of ¥271.98 million after deducting issuance costs[128]. - The cumulative amount of raised funds used by the end of 2024 is ¥276.09 million, with ¥300.53 million remaining unused[128]. - The company has committed to several investment projects, including a project in Shaanxi Province with a total investment of ¥15 million[130]. Human Resources and Employee Engagement - The company is enhancing employee care through a comprehensive 360-degree employee care system, promoting a culture of happiness and productivity[145]. - The number of R&D personnel increased by 8.70% from 69 in 2023 to 75 in 2024, with R&D personnel accounting for 11.05% of the total workforce[117]. - The company’s remuneration system for directors and senior management is linked to performance and individual capabilities[196]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue increase of 25% based on current market trends and user acquisition strategies[3]. - Future guidance includes maintaining a net profit margin of at least 15% while continuing to invest in growth initiatives[10]. - The company has outlined a future revenue guidance of 300 million for the next fiscal year, representing an expected growth of 9.2%[175].

陕西盘龙药业集团股份有限公司 2025 年第一季度报告 证券代码：002864 证券简称：盘龙药业 公告编号：2025-015 陕西盘龙药业集团股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 250,212,341.68 | 210,115,513.50 | 19.08% | | 归属于上市公司股东的净利 | 31,249,274.14 | 3 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-011 陕西盘龙药业集团股份有限公司 关于公司《药品生产许可证》变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于近期完成了《药品生 产许可证》的变更登记并取得了陕西省药品监督管理局换发的《药品生产许可证》， 同意公司《药品生产许可证》副本新增车间和生产线情况。现将相关情况公告如下： 一、《药品生产许可证》的基本情况 企业名称：陕西盘龙药业集团股份有限公司 注册地址：陕西省商洛市柞水县盘龙生态产业园 社会信用代码：91610000223472005U 法定代表人：谢晓林 企业负责人：谢晓林 质量负责人：徐远涛 生产负责人：孟重 有效期至：2025 年 12 月 16 日 | 生产地址 | 车间 | 生产线 | 范围 | | --- | --- | --- | --- | | 陕西柞水盘龙 | 中药配方颗粒车 | 中药配方颗粒生 | 中药饮片(【净制、切制、 | | 生态产业园 | 间 | 产线 | 炒制(清炒、麸炒、砂炒)、 | | | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 陕西盘龙药业集团股份有限公司（以下简称"公司"）第四届董事会第二十 三次会议通知于 2025 年 3 月 18 日以邮件、电话方式通知各位董事。本次会议于 2025 年 3 月 21 日在西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医 药股份有限公司二楼会议室采用现场与通讯相结合方式召开。会议应出席董事 9 名，实际出席董事 9 名（其中任海云女士、牛晓峰先生、焦磊鹏先生以通讯方式 出席本次会议）。会议由公司董事长谢晓林先生召集并主持，公司监事及高级管 理人员列席了本次会议。本次会议的召集和召开均符合《中华人民共和国公司法》 等有关法律法规及《陕西盘龙药业集团股份有限公司章程》的有关规定。 二、董事会会议审议情况 1、审议并通过了《关于向中国农业银行股份有限公司柞水县支行申请一亿 元短期流动资金贷款暨公司实际控制人提供担保的议案》 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 公司因发展需要拟加强与金融机构的合作，计划向中国农业银行股份有限公 司柞水县支行申请不超 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-009 陕西盘龙药业集团股份有限公司 关于注销部分募集资金账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、2022 年度可转换公司债券募集资金 经中国证券监督管理委员会许可[2021]3323 号核准，公司于 2022 年 3 月 3 日发行可转换公司债券 276 万张，每张面值为人民币 100 元，发行价为每张人民 币 100 元，募集资金总额为人民币 276,000,000.00 元，已由承销机构中泰证券股 份有限公司于 2022 年 3 月 9 日汇入公司开立在招商银行西安分行曲江支行账号 为 129907180410909 的银行账户 150,625,400.00 元，开立在中国银行西安太白小 区支行账号为 102498736801 的银行账户 49,568,400.00 元，开立在上海浦东发展 银行股份有 限 公 司 西 安 分 行 账 号 为 72010078801600005471 的银行账户 73,825,067.92 元，共汇入人民币 274,018,867.92 ...

若交易顺利实施，将对公司经营业绩产生积极影响。 人民财讯3月19日电，博济医药(300404)3月19日晚间公告，近期公司、全资子公司广州华圣制药有限公 司（简称"华圣制药"）与陕西盘龙药业集团股份有限公司（简称"盘龙药业"）共同签订《技术转让合同 书》，三方协商，华圣制药将"硫酸氨基葡萄糖胶囊"的技术转让给盘龙药业，转让经费总计450万元。 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-008 陕西盘龙药业集团股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2024 年 3 月 13 日召开第四届董事会第十八次会议和第四届监事会第十五次会议，审议通过了 《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金 以集中竞价交易的方式进行股份回购，用于员工持股计划或者股权激励。本次回 购的资金总额不低于人民币 1,000 万元（含），不超过人民币 2,000 万元（含）， 回购价格不超过 45.00 元/股（含），回购期限自公司董事会审议通过本次回购 股份方案之日起 12 个月内。具体内容详见公司于 2024 年 3 月 14 日、2024 年 3 月 16 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于以集中竞价交易方式 回购公司股份方案的公告》《回购报告书》。 截至本公告披露日，本次回购方案自公司董事会审议通过之日起已满 12 个 月，且本次回购 ...

一、回购股份的进展情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在每个月的前三个交易日内披露截至 上月末的回购进展情况，现将公司回购股份的进展情况公告如下： 截至 2025 年 2 月 28 日，公司通过回购专用证券账户使用自有资金以集中竞 价方式累计回购公司股份数量为 373,500 股，占公司总股本的 0.35%。最高价格 为 28.50 元/股，最低价格为 25.71 元/股，合计支付的总金额为人民币 10,002,880.25 元（不含交易费用）。 证券代码：002864 证券简称：盘龙药业 公告编号：2025-007 陕西盘龙药业集团股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2024 年 3 月 13 日 召开第四届董事会第十八次会议和第四届监事会第十五次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金以集 中竞价交易的方式进行股份回购，用于员工 ...